Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• ErbB2 (Epidermal Growth Factor Receptor 2) is overexpressed in various human cancers.
• Unlike EGFR, ErbB2 typically resists endocytosis.
• Heat shock protein 90 (HSP90) inhibitors, like geldanamycin, can down-regulate ErbB2.

Purpose of the Study:

• To investigate the molecular mechanisms underlying geldanamycin-induced ErbB2 down-regulation.
• To determine the role of endocytosis and lysosomal degradation in ErbB2 clearance.
• To elucidate the involvement of dynamin, clathrin, and proteasomal pathways.

Main Methods:

• Utilized SKBr3 cancer cells.
• Investigated ErbB2 endocytosis using dynamin and clathrin knockdown.
• Assessed protein degradation pathways (lysosomal vs. proteasomal).
• Employed electron microscopy for subcellular localization analysis.

Main Results:

• Geldanamycin induces endocytosis and lysosomal degradation of full-length ErbB2.
• ErbB2 endocytosis is dependent on dynamin and clathrin.
• Proteasomal degradation occurs when ErbB2 is retained at the plasma membrane.
• Proteasomal activity is required for sorting internalized ErbB2 to lysosomes, not for initial endocytosis.

Conclusions:

• Geldanamycin promotes ErbB2 lysosomal degradation via a clathrin- and dynamin-dependent endocytic pathway.
• Proteasomal activity is crucial for the subsequent lysosomal sorting of internalized ErbB2.
• Understanding these mechanisms is vital for designing novel cancer therapies combining HSP90 inhibitors and proteasome inhibitors.